Retatrutide 30mg | Vitality & Anti Aging Research Peptide

Retatrutide (LY3437943) is a synthetic acylated peptide developed by Eli Lilly & Company currently in Phase 3 clinical development. It is classified as a unimolecular triple agonist, a single peptide molecule that simultaneously activates the glucagon like peptide-1 receptor (GLP-1R), the glucose dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR). This triple receptor co-activation represents a pharmacological advance beyond the GLP-1R monoagonists (semaglutide, liraglutide) and GLP-1R/GIPR dual agonists (tirzepatide) that preceded it in the incretin research field.

The scientific rationale for triple receptor co-activation is grounded in the complementary and partially non overlapping biology of the three receptor systems. GLP-1R drives glucose dependent insulin secretion from pancreatic beta cells, reduces appetite via hypothalamic circuits and in non pancreatic tissues activates AMPK, a central energy sensor that promotes mitochondrial biogenesis, fatty acid oxidation and glucose uptake independently of insulin. AMPK is also a canonical target of longevity interventions: metformin, rapamycin and caloric restriction all converge on AMPK/mTOR pathway modulation. GIPR in adipocytes phosphorylates and activates hormone sensitive lipase (HSL) and perilipin-1, releasing stored triglycerides as free fatty acids for mitochondrial beta oxidation providing cellular energy substrate mobilisation research. GCGR in brown adipose tissue (BAT) and liver drives two of the most scientifically compelling mechanisms in the compound’s anti aging research profile: BAT UCP1/PGC-1α upregulation (thermogenesis and mitochondrial biogenesis) and hepatic FGF21 secretion.

FGF21 and the longevity connection represent the most pharmacologically novel aspect of Retatrutide in the anti aging research context. Fibroblast growth factor 21 (FGF21) is a hepatokine produced in response to GCGR activation, PPAR-α agonism (fasting, ketogenic states) and caloric restriction. It signals through a co-receptor complex of FGFR1c and β-Klotho, which is highly expressed in white adipose tissue, the hypothalamus and skeletal muscle. FGF21 promotes whole body insulin sensitivity, reduces lipotoxicity, enhances mitochondrial oxidative phosphorylation efficiency and activates stress response pathways (via PGC-1α and SIRT1). In transgenic mouse models overexpressing FGF21, median lifespan is extended by approximately 36%, one of the most robust longevity phenotypes observed in rodent models. The ability of Retatrutide to pharmacologically induce FGF21 production through GCGR activation makes it a research tool for studying FGF21-mediated metabolic longevity biology.

BPeptide supplies Retatrutide 30mg lyophilized powder at ≥99% purity for use in cAMP reporter assays, receptor binding studies, FGF21 secretion assay panels, adipocyte lipolysis experiments, thermogenesis gene expression studies (UCP1, PGC-1α) and other validated laboratory research applications.